Moleculin Biotech is trading at $5.56, down 5.60% after hours versus the regular-session close, as broader risk-off sentiment may be weighing on shares.
- No clear company-specific announcement dated October 22 explains the decline; the latest company news found was an October 20 update on its AML trial.
- Reuters reported technology stocks weakened amid AI-spending concerns and rising oil prices, while the Nasdaq fell more than 2% during the session.
- Available evidence points to a market-driven explanation, not a confirmed company catalyst.